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PERKEMBANGAN DAN PENGESAHAN KAEDAH KCPT BAGI PENENTUAN  
HALOPERIDOL DAN HALOPERIDOL TERTURUN SECARA SERENTAK DI DALAM 
PLASMA : APLIKASI DALAM KAJIAN FARMAKOKINETIK 
 
 
Abstrak 
 
Haloperidol merupakan suatu drug antipsikotik yang tipikal dan secara 
kimianya daripada kumpulan butirofenon. Suatu kaedah kromatografi cecair 
berprestasi tinggi yang peka dan selektif dengan pengesan ultra-lembayung telah 
diperkembangkan bagi penentuan haloperidol dan haloperidol terturun secara serentak 
di dalam plasma. Drug dikesan pada 230 nm. Pemisahan kromatografi dilakukan 
dengan menggunakan turus KCPT Inertsil C8-3 (150 x 4.6 mm, 5µm). Fasa bergerak 
yang digunakan terdiri daripada 50 mM larutan penimbal fosfat (pH 5.0) – metanol 
(51:49, v/v) dengan kadar aliran fasa bergerak 1.0 ml/min. Pengekstrakan cecair-
cecair yang mudah telah dihasilkan dan pirimetamina digunakan sebagai piawai 
dalaman. Purata peratus pengembalian bagi haloperidol, haloperidol terturun dan 
pirimetamina adalah 82.4, 82.1 dan 82.0% masing-masing. Kaedah ini menunjukkan 
selektiviti yang baik di mana tidak terdapat gangguan daripada puncak-puncak drug 
antipsikotik yang lazim digunakan. Keluk kalibrasi adalah linear bagi julat kepekatan 1-
60 ng/ml dengan pekali korelasi ( r ) > 0.999. Peratus pekali variasi bagi kepersisian 
kaedah dalam sehari dan hari ke hari adalah kurang daripada 5%. Had pengesanan 
dan had kuantifikasi bawah adalah 0.5 ng/ml dan 1.0 ng/ml masing-masing bagi 
haloperidol dan haloperidol terturun. 
 
Stok piawai yang dilarutkan dalam metanol didapati stabil selama tiga 
bulan pada suhu -20°C. Manakala sampel-sampel plasma didapati stabil selama 6 
 xviii
bulan pada suhu-20°C and -85°C Kaedah ini telah diaplikasi dengan jayanya dalam 
kajian farmakokinetik haloperidol di dalam tikus di mana haloperidol diberikan secara 
dos oral (2.5 mg/kg). Nilai purata t1/2, Cmax, tmax, AUC(0-∞), CL dan Vd adalah  6.2 ± 2.6 
h, 24.9 ± 7.2 ng/ml, 2.0 ± 1.9 j, 214.1 ± 76.0 ng.j/ml, 213.0 ± 61.9 ml/min/kg dan 110.3 
± 46.3 l/kg masing-masing. Kaedah analisis bagi haloperidol dan haloperidol terturun 
yang telah dihasilkan didapati sesuai bagi kajian farmakokinetik. 
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DEVELOPMENT AND VALIDATION OF HPLC METHOD FOR SIMULTANEOUS 
DETERMINATION OF HALOPERIDOL AND REDUCED HALOPERIDOL IN 
PLASMA: APPLICATION IN PHARMACOKINETIC STUDY 
 
 
 
Abstract 
 
 
 
Haloperidol is a typical antipsychotic drug that chemically belongs to 
butyrophenone group. A sensitive and selective reversed-phase HPLC method with 
ultraviolet detection was developed for the simultaneous determination of haloperidol 
and reduced haloperidol in plasma. Drugs were detected at 230 nm.  The 
chromatographic separation was performed on an Inertsil C8-3 (150 x 4.6mm, 5 µm) 
HPLC column. Mobile phase composed of 50 mM phosphate buffer pH 5.0 and 
methanol (51:49, v/v) and eluted at 1.0 ml/min. A simple liquid-liquid extraction was 
carried-out using pyrimethamine as an internal standard. The mean extraction recovery 
for haloperidol, reduced haloperidol and pyrimethamine were 82.4, 82.1 and 82.0% 
respectively. The method showed good selectivity with respect to commonly 
administered psychotropic drugs. Calibration curve was linear over the concentration 
range 1 - 60 ng/ml with the correlation coefficient (r) > 0.999. The within-day and day-to 
-day assay precision was less than 5%. Limit of detection and lower limit of 
quantification were 0.5 ng/ml and 1 ng/ml respectively for haloperidol and reduced 
haloperidol.  
 
Stock standard of haloperidol and reduced haloperidol in methanol were 
stable up to three months at -20°C. Plasma samples spiked with haloperidol and 
reduced haloperidol was stable up to 6 months at -20°C and -85°C. The method was 
successfully applied to pharmacokinetic study of haloperidol in rats following oral dose 
of haloperidol (2.5 mg/kg). The mean t1/2, Cmax, tmax, AUC (0-∞), CL and Vd were 6.2 ± 2.6 
 xx
h, 24.9 ± 7.2 ng/ml, 2.0 ± 1.9 h, 214.1 ± 76.0 ng.h/ml, 213.0 ± 61.9 ml/min/kg and 
110.3 ± 46.3 l/kg respectively. The analytical method for haloperidol and reduced 
haloperidol assay is found to be suitable for pharmacokinetic studies. 
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CHAPTER 1 
INTRODUCTION 
 
1.1  PSYCHOSIS 
Psychosis is a mental disorder which involves striking disturbances of 
thought, perception, affect, and behaviour (Pantelis et al., 2003). The expression of 
psychotic symptoms varies over time and across patients, however the cumulative 
effects of the illness are always severe and usually long lasting (Sadock & Sadock, 
2000). There are various types of psychotic disorders such as anxiety, bipolar disorder 
(manic disorder), depression and schizophrenia (Grilly, 1994). These disorder a briefly 
discussed in the following sections. 
 
1.1.1 ANXIETY 
Anxiety is a normal response to psychological stress induced by either 
physical or perceived threat. However, a malfunctioning anxiety response could lead to 
anxiety disorders. Anxiety disorders are further divided into five types; such as panic 
disorder, social phobia, obsessive compulsive disorder, generalised anxiety disorder 
and posttraumatic stress disorder (Leveleki et al., 2006; Ballenger, 1999). Patients 
suffering from anxiety disorder are usually treated either by medication or 
psychotherapy (Ballenger, 1999). 
 
1.1.2 MANIA OR BIPOLAR DISORDER 
Mania or bipolar disorder is a brain disorder that causes unusual shifts 
in a person’s mood, energy and ability to function. During a manic episode, the mood 
disturbances are severe enough to cause significant impairment in occupational 
functioning or in otherwise normal social activities (Schapiro, 2005). Bipolar disorder is 
further classified into two groups namely Bipolar I and Bipolar II. Bipolar I is 
characterised by one or more manic or mixed episodes. Bipolar II is characterised by 
 2 
recurrent episodes of major depression and hypomania.  Bipolar disorder affects 
approximately three to five percent of the world’s population, and affects both sexes 
equally in all age group (Shastry, 2005). 
 
1.1.3  DEPRESSION 
  Depression is defined as a feeling of intense sadness. Depressed 
individuals tend to be obsessed with personal failings, are apathetic and socially 
withdrawn (Malatynska & Knapp, 2005). Depression disorder can be transmitted in the 
form of negative emotions from living or non-living beings to susceptible host. 
Therefore, depression is also known as communicable disorder (Kalra, 2004). 
Symptoms of depression disorder can last periods of time, sometimes several to years 
(Gard, 2001).  
 
1.1.4  SCHIZOPHRENIA 
Schizophrenia is a complex cognitive disorder comprising of a variety of 
alterations in attention, working memory, language, response monitoring and inhibition 
(Freedman, 2003). Schizophrenia is treated as a debilitating disorder of the central 
nervous system. Its symptoms are divided into two classes namely positive symptoms 
and negative symptoms. Positive symptoms include hallucinations, delusions, 
conceptual disorganization, where negative symptoms include social withdrawal, 
blunted affect, and poverty of speech (Sawa & Snyder, 2002; Donaldson et al., 1983). 
This disorder reduces the ability of the individual to interact with the social. 
Schizophrenia affects about 1% of the world's population (Buchanan & Carpenter, 
2000). All these types of mental disorders mentioned above are treated with 
antipsychotic drug that will be described in the following section. 
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1.2         ANTIPSYCHOTIC DRUG 
  The term antipsychotic is applied to a group of drugs used to treat 
psychosis. These classes of drugs were originally called 'neuroleptics' (from the Latin 
root which mean to grasp the neuron) (Nicholas, 2004). Antipsychotic drugs are 
generally divided in two types; that is typical antipsychotic drug and atypical 
antipsychotic drug. 
 
1.2.1  TYPICAL ANTIPSYCHOTIC DRUG 
Typical antipsychotics are also known as major tranquilizers because of 
their tranquilising and sedating effects when taken in large doses. Typical antipsychotic 
drugs are effective primarily against positive symptoms of schizophrenia. Such drugs 
include haloperidol (HP), chlorpromazine, perphenazine, thioridazine and 
trifluoperazine are examples of typical antipsychotic drug (Fig. 1.1). Chlorpromazine 
was the first typical antipsychotic drug used in 1952 to treat schizophrenic patients 
(Edliner et al., 2005). Antipsychotic properties of typical antipsychotics are achieved 
through the antagonistic effect on dopamine receptors.  
 
The typical antipsychotic drugs used to treat schizophrenia are highly 
effective. In particular, HP, the most widely used typical antipsychotic is very efficient in 
treating the positive symptoms of schizophrenia. The most predominant among these 
symptoms are dystonia, parkinsonian-like syndrome, and tardive dyskinesia 
(Andreassen et al., 1996). 
 
1.2.2  ATYPICAL ANTIPSYCHOTIC DRUG 
Atypical antipsychotic drugs are used to treat schizophrenic patients 
and results less extrapyramidal side effects. Compared to the older ‘typical’ 
antipsychotic, the atypical antipsychotic drugs are equally effective against the positive 
symptoms and the negative symptoms of schizophrenia. Atypical antipsychotic drugs 
 4 
block both dopamine and serotonin (5-hyroxytryptamine) receptors. These combined 
effects on both dopamine and serotonin (5-hyroxytryptamine) receptors explain the 
lower extrapyramidal side effects of atypical antipsychotic drugs. Examples of atypical 
antipsychotic drugs are ariprazole, risperidone, clozapine, olanzapine, quetiapine and 
ziprasidone (Fig. 1.2).  
 
1.3  HALOPERIDOL 
HP is {4-[4-(p-chlorophenyl)-4-hydroxypiperidino] 4’-flurobutyrophenone}  
a typical butyrophenone antipsychotic drug. HP is a tertiary amine that occurs as a 
white or almost white powder, is practically insoluble in water, and is slightly soluble in 
alcohol, methanol (MeOH) and methylene chloride. The melting point of HP is 150 to 
153°C. The empirical formula for HP is C21H23ClFNO3  (B P, 2003). The drug has a 
pKa value of 8.3 (AHFS, 2000). 
 
 HP is effective in the treatment of many psychotic disorders such as 
hyperactivity, agitation and mania (Robert & Allain, 2001). HP effectively treats positive 
symptoms of schizophrenia (Glick et al., 2001) while ineffective against negative 
symptoms of schizophrenia. HP is also used in the treatment of neurological disorders 
such as Gilles de la Tourette syndrome, Huntington’s chorea and acute/chronic brain 
syndrome (Silver et al., 2001; Barr et al., 1988; Maltbie & Cavenar, 1977). Long-term 
use of HP can result in side effects resembling Parkinson’s disease and tardive 
dyskinesia, an irreversible motor disorder (Fuxe et al., 1989).  
 
Nearly 40 years after its discovery, HP is still one of the most popular 
drug used for the management of various classes of psychosis. The pharmacology of 
HP has been extensively reported (Janssen, 1967). Different assay methods have 
been described in the literature, which will be discussed in the following section.  
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1.3.1   ASSAY OF HP AND RH IN BIOLOGICAL FLUIDS 
Several analytical methods have been reported in the literature for the 
determination of either HP or RH or both drugs in biological fluids. All these methods 
involve various types of detection techniques (Table 1.1). Selection of a detection 
technique depends on the types of analytes, and the sensitivity required. For routine 
analysis, the most commonly used detection techniques are ultraviolet (UV) and 
electrochemical (EC) methods.  
 
A number of techniques are available in the literature for the 
determination of HP in plasma. Some of these include gas chromatography (Bianchetti 
& Morselli, 1978), radioimmunoassay (Clark et al., 1977) and UV methods (Kogan et 
al., 1983; Miyazaki & Arita, 1981).  Pharmacological studies showed that reduced 
haloperidol (RH), metabolite of HP is pharmacologically active. Therefore, a routine 
method for determination of plasma level should include both HP and RH. 
Simultaneous determinations of HP and RH in human plasma by HPLC system 
coupled with UV (Miller & Devane, 1986; Cahard et al., 1990; Park et al., 1991) or EC 
(Aravagiri et al., 1994; Korpi et al., 1983; Eddington & Young, 1988) method have been 
reported.  
 
Although HPLC with EC detection is highly sensitive, it involves the use 
of high voltage that can be problematic in monitoring HP plasma levels (Parkinson, 
1985). Furthermore, increased interference from co-administered drugs is observed in 
assay (Pan et al., 1998). Several other methods reported in the literature include gas 
chromatography with nitrogen-phosphorus or electron-capture detector (Bianchetti & 
Morselli, 1978; Franklin, 1980; Forsman et al., 1974) and radioimmunoassay (Clark et 
al., 1977; Browning et al, 1985), are relatively time consuming and not a common 
routine method in many therapeutic drug monitoring laboratories. The 
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radioimmunoassay method is very cumbersome and lack specificity and sensitivity and 
with it, RH is determined by an indirect method.  
 
Recently, liquid chromatography in combination with mass 
spectrometric detection (Hempenius et al., 1999; Hoja et al., 1997) has been reported 
for the analysis of HP. Sophisticated detector such as mass spectrometry coupled with 
liquid chromatography or gas chromatography is admittedly highly sensitive. However, 
it is very expensive and requires great expertise in order to operate. With such 
considerations in mind, a method based on UV detection is still the most practical for 
routine applications and therefore is the method of choice in this thesis.  
 
For analysis of drugs and its metabolites in plasma, sample preparation 
is very important. HP and RH were extracted from biological fluids either by liquid-liquid 
extraction (LLE) or solid phase extraction (SPE) (Table 1.2). However, LLE is the most 
popular and convenient method for routine analysis of HP and RH determinations 
(Korpi et al., 1983; Miller & Devane, 1986; Hariharan et al., 1989; Park et al., 1991). 
Only a few groups used the SPE method (Hempenius et al., 1999; Hoffman & Edkinds, 
1994; Cahard et al., 1990). LLE extraction involves single, double or multiple step of 
extraction. Extraction efficiency partly depends on the types of extraction solvents, 
sample preparation pH, back extraction solvents and physiochemical properties. 
Different types of extraction solvents are used to extract drug from plasma. In most 
case mixtures of organic non-polar and polar solvents are employed. For HP and RH 
determinations commonly used non-polar solvents are pentane, hexane and heptane 
and polar solvents are isoamyl alcohol and isopropanol (Table 1.2). However, from the 
reported recovery data presented in Table 1.2 it is difficult to conclude which 
combination of extraction solvents were the best, since extraction performance depend 
on several factors.  
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To keep drugs in a neutral state, basifying agents are generally added 
to plasma. Sodium hydroxide (Hariharan et al., 1989; Miller & Devane, 1986; Jatlow et 
al., 1982) and sodium carbonate (Aravagiri et al., 1994; Midha et al., 1988) at different 
concentrations were used as basifying agents for HP determination in plasma.  
 
Different types of solvents are used to back extract the drug from 
organic phase into aqueous phase.  For HP and RH determination hydrochloric acid 
(Midha et al., 1988; Miller & Devane, 1986; Hoja et al., 1997), perchloric acid 
(Hariharan et al., 1989) and sulfuric acid (McBurney & George, 1984; Park et al., 1991) 
were used as back extraction solvents. However, organic acid (perchloric acid and 
acetic acid) are the preferred back extraction solvent as compared to inorganic acid 
(hydrochloric acid and sulphuric acid). A much cleaner blank chromatogram was 
obtained using perchloric acid rather than hydrochloric acid or sulphuric acid 
(Hariharan et al., 1989).  
 
1.3.2  PHARMACOLOGY OF HP 
A pharmacological action of drug is dependent upon its chemical 
structure, any change in chemical structure may change the drug action. The exact 
drug action also depends on its binding affinity to the receptor types. Drugs combine 
with these receptors to produce their pharmacological effect (Gard, 2001).  
 
Pharmacological activity of HP is related to its affinity for the dopamine 
receptors. (Beuger et al., 1996; Creese et al., 1976; Seeman & Lee, 1975; Seeman et 
al., 1974). Dopamine receptors are classified into five subtypes such as D1, D2, D3, D4 
and D5 (Dearry et al., 1990; Grandy et al., 1991; Monsma et al., 1990; Sokoloff et al., 
1990; Sunahara et al., 1991; Vantol et al., 1991). These receptors are further divided 
into two subfamilies such as the D1-like receptors (D1 and D5) and the D2-like receptors 
(D2, D3 and D4)(Tarazi, 2001). The binding of HP to the postsynaptic D2-like receptors 
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is believed to mediate the therapeutic effects (Creese et al., 1976; Seeman & Lee, 
1975; Seeman et al., 1974). In addition to the specific functions of several subtypes, 
dopamine receptors also have distinct functions based on their location at the neuron, 
i.e. pre-synaptically or post-synaptically (Nagy et al., 1978). Post-synaptic dopamine 
receptors are necessary for signal initiations or transmission, whereas pre-synaptic 
dopamine receptors, located on the cell bodies and axon terminals, function as  
autoreceptors through which the release of  dopamine can be regulated. 
 
HP, which is a dopamine antagonist, mimics the dopamine in binding to 
the dopamine receptor. There appears to be a very narrow range between the effective 
therapeutic dose for the management of acute psychotic disorder and that, which 
causes extrapyramidal side effects (AHFS, 2000). Therefore, the determination of 
antipsychotic drugs plasma concentration in psychiatric patient is important, especially 
in case of the HP, due to large variability between individuals. When HP is metabolised 
in the liver it produces the metabolite RH. This reduced metabolite, RH is then oxidised 
back to HP. Therefore, the influence of HP and RH on clinical responses requires the 
monitoring of plasma levels for better patient management during HP therapy. 
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Table 1.1 Summary of analytical method for HP determination in biological matrix. 
References  Detector Internal standard Column Mobile phase Extraction 
method 
LOQ/ 
LOD 
Recovery 
(%) 
Miyazaki & 
Arita. (1981) 
 
 
Jatlow et al. 
(1982) 
 
 
Kogan et al. 
(1983) 
 
 
 
 
 
Korpi et al. 
(1983) 
 
 
Dhar & Kutt. 
(1984) 
 
 
 
Miller & 
Devane. (1986) 
 
 
 
 
HPLC-UV 
250 nm 
 
 
HPLC-UV 
195 nm 
 
 
HPLC-UV  
254 nm 
 
 
 
 
 
HPLC-EC 
 
 
 
HPLC-UV 
254 nm 
 
 
 
HPLC-UV 
196 nm 
 
 
 
 
 
Diphenylamine  
 
 
 
Desipramine  
 
 
 
Chlorohaloperidol 
 
 
 
 
 
 
Chlorohaloperidol 
 
 
 
Chloro-substitute 
analog   
 
 
 
Chlorohaloperidol 
 
 
 
 
 
   
C18 Nucleosil 
250 x 4 mm, 
i.d. 5µm 
 
C18 Bio-sil ODS 
250 mm 
i.d. 10 µm 
 
C18 Absorbosphere 
100 x 4.6 mm, 
 i.d. 3 µm 
 
 
 
 
µBondapak CN 
300 x 3.9 mm, 
i.d. 10 µm 
 
C8 bonded RP 
250 x 4.6 mm, 
i.d. 5 µm 
 
 
C18 
250 x 4.6 mm, 
i.d. 10 µm 
 
 
 
Methanol-0.2 M 
ammonium acetate 
(63:37, v/v) 
 
Acetonitrile-Potassium 
dihydrogen phosphate 
pH3.8-4 (40:60, v/v) 
 
Acetonitrile-0.4 ml 
concentrated sulfuric 
acid, 1.1 g tetramethyl 
ammonium chloride, 0.5 
ml triethylamine per liter 
(45:55, v/v) 
 
Acetonitrile-potassium 
phosphate buffer pH 
6.8 (45:55, v/v) 
 
Acetonitrile-methanol-
16.5mm disodium 
hidrogen phosphate 
pH5 (45:25:30, v/v/v) 
 
Acetonitrile-100 mm 
monobasic potassium 
phosphate pH 3.8-4 
(55:45, v/v) flow rate : 
2.0 ml/min 
 
 
LLE 
 
 
 
LLE 
 
 
 
LLE 
 
 
 
 
 
 
LLE 
 
 
 
LLE 
 
 
 
 
LLE 
 
 
 
 
 
 
5 ng/ml 
(LOD) 
 
 
1 ng/ml 
(LOD) 
 
 
2 ng/ml 
(LOD) 
 
 
 
 
 
0.5 ng/ml 
(LOD) 
 
 
1 µg/l 
(LOD) 
 
 
 
2 ng/ml 
(LOD) 
 
 
 
 
 
 
HP :102% 
 
 
 
HP :78% 
 
 
 
HP :80% 
 
 
 
 
 
 
HP:92% 
RH:93% 
 
 
HP:89% 
 
 
 
 
HP:86% 
RH:92% 
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Table 1.1 continued 
References  Detector Internal standard Column Mobile phase Extraction 
method 
LOQ/ LOD Recovery 
(%) 
Eddington & 
Young.  (1988) 
 
 
 
 
Hariharan et 
al. (1989) 
 
 
Cahard et al. 
(1990) 
 
 
 
 
Wilhelm & 
Kemper. 
(1990) 
 
 
Park et al. 
(1991) 
 
 
 
 
Aravagiri et al. 
(1994) 
 
HPLC-EC 
 
 
 
 
 
HPLC-
coulometri 
 
 
HPLC-UV 
220 nm 
 
 
 
 
Photo-
diode 
 
 
 
HPLC-UV 
214 nm 
 
 
 
 
HPLC-EC 
 
Chlorohaloperidol 
 
 
 
 
 
Bromoperidol  
 
 
 
Chlorohaloperidol 
 
 
 
 
 
Clonazepam   
 
 
 
 
Bromoperidol 
 
 
 
 
 
Chlorohaloperidol 
 
Nitrile bonded LC-
PCN  
150 x 4.6 mm, 
i.d. 5 µm 
 
 
C8 RP (DB) 
250 x 4.6 mm, 
i.d. 5 µm 
 
C18 µBondapak 
300 x 3.9 mm, 
i.d. 10 µm 
 
 
 
Silica 100 RP-18 
120 x 4 mm,  
i.d. 5 µm 
 
 
C18- Nova Pak  
150 x 2.9 mm, 
i.d. 4 µm 
 
 
 
Ultrasphere Cyano  
250 x 4.6 mm, 
i.d. 5 µm 
 
Acetonitrile-1-propanol-
10 mm dipotassium 
hidrogen phosphate pH 
6.8 (30 :20 :50, v/v/v) 
flow rate : 1.1ml/min 
 
Acetonitrile-methanol-
50 mM KH2PO4 pH 7 
(20:40:40, v/v/v) 
 
Acetonitrile-water-0.025 
M potassium 
dihydrogenphosphate 
(45:5:50, v/v/v) flow 
rate 0.8 ml/min 
 
Gradient : ethanol-
acetonitrile-0.05 M 
phosphate buffer pH2.9 
(22:8:70, v/v/v) 
 
Acetonitrile-methanol-
0.5 M potassium 
dihydrogen phosphate 
(31:11:58, v/v/v/) 
Flow rate : 0.6 ml/min 
 
Acetonitrile-methanol-
0.04M ammonium 
acetate pH 6.8 (86:6:8, 
v/v/v) 
 
SPE 
 
 
 
 
 
LLE 
 
 
 
SPE 
 
 
 
 
 
SPE 
 
 
 
 
LLE 
 
 
 
 
 
LLE 
20 pg 
(LOD) 
 
 
 
 
50 ng/l 
(LOD) 
 
 
1 ng/ml 
(LOQ) 
 
 
 
 
450 pg/ml 
(LOQ) 
 
 
 
0.5 ng/ml 
(LOD) 
 
 
 
 
0.1 ng/ml 
(LOQ) 
HP :93% 
RH :90% 
 
 
 
 
HP :83% 
RH :76% 
 
 
 
 
 
 
 
 
HP :101% 
 
 
 
 
HP :95% 
RH :73% 
 
 
 
 
HP :68% 
RH:86% 
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Table 1.1 continued 
References  Detector Internal standard Column Mobile phase Extraction 
method 
LOQ/ LOD Recovery 
(%) 
Hoffman & 
Edkins. (1994) 
 
 
 
Hoja et al. 
(!997) 
 
 
Pan et al. 
(1998) 
 
 
 
 
 
 
 
Hempenius et 
al. (1999)  
 
 
Titier et al. 
(2003) 
HPLC-
coulometri 
 
 
 
LC-EC-MS 
 
 
 
HPLC-UV 
220 nm 
 
HPLC-EC 
 
 
 
 
 
LC-MS 
 
 
 
HPLC-UV 
240 nm 
Chlorohaloperidol 
 
 
 
 
Chlorohaloperidol 
 
 
 
Chlorohaloperidol  
 
 
 
 
 
 
 
 
Haloperidol D4   
 
 
 
Methylrisperidone  
Microsorb –  
100 x 4.6 mm, 
i.d. 3 µm 
 
 
C18 Nucleosil 
150 x 1 mm, 
i.d. 5 µm 
 
C18 Symmetry 
150 x 3.9 mm, 
i.d. 5 
Altima CN 
250 x 4.6 mm, 
i.d. 5 µm 
 
 
 
C18 Symmetry  
100 x 4.6 mm, 
i.d. 3.5 µm 
 
C8 Symmetry 
i.d. 250 x 4.6 mm, 
 
Methanol-50mM 
sodium phosphate pH 
6.5 (50:50, v/v)  
Flow rate : 0.5ml/min 
 
Acetonitrile-0.04M 
ammonium formate 
(45:55, v/v) 
 
Acetonitrile-0.02M 
sodium dihydrogen 
phosphate pH 3.8 
(29:71, v/v) 
Acetonitrile-Methanol-
0.04M sodium 
dihydrogen phosphate 
pH 6.8 (35:20:45, v/v/v)l 
 
Methanol-0.2% formic 
acid (50:50, v/v) 
 
 
Gradient : Acetonitrile-
50mM NaH2PO4 
SPE 
 
 
 
 
LLE 
 
 
 
LLE 
 
 
 
 
 
 
 
 
SPE 
 
 
 
LLE 
0.5 ng/ml 
(LOD) 
 
 
 
0.075 
ng/ml 
(LOD) 
 
2 ng/ml 
(LOQ) 
 
0.5 ng/ml 
(LOQ) 
 
 
 
 
0.1 (LLQ) 
 
 
 
5 ng/ml 
(LOQ) 
HP :80% 
 
 
 
 
HP :58% 
RH:70% 
 
 
HP :99-
104% 
 
HP :83-
121% 
 
 
 
 
 
 
 
 
HP:69% 
Abbreviation: HPLC-UV = High performance liquid chromatography-Ultraviolet detector; HPLC-EC= High performance liquid 
chromatography-electrochemical detector; LC-EC-MS= liquid chromatographic-electrospray mass spectrometric; LC-MS= liquid 
chromatographic mass spectrometric; i.d.= internal diamension; mm=milimeter;  µm=mikrometer; nm=nanometer; LLE = liquid-liquid 
extraction; SPE= solid phase extraction; LLOQ=lower limit of quantification, LOQ=limit of quantification; LOD=limit of detection;  
HP=haloperidol; RH=reduced haloperidol. 
 14
Table 1.2 Summary of extraction method for HP determination in biological matrix. 
 
References  Extraction solvent Basifying agent Back extraction solvent Reconstitute solvent 
 
 Titier et al. (2003) Hexane : isoamylalcohol 
(99:1, v/v) (7 ml) 
 
Sodium hydroxide 
 (2 N, 100 µl)) 
Hydrochloric acid(0.05 
M, 200 µl) 
Direct injection 
Pan et al. (1998) Hexane : isoamylalcohol 
(100:2, v/v) (5 ml) 
 
Sodium hydroxide 
 (2 N, 200µl) 
Hydrochloric acid (0.1 
N, 150 µl) 
Mobile phase 
Hoja et al. (1997) Hexane : isoamylalcohol 
(99:1, v/v) (8 ml) 
 
Sodium hydroxide 
 ( 2M, 500µl) 
Hydrochloric acid (0.2 
M, 1ml) 
Mobile phase 
(50 µl) 
Aravagiri et al.  
(1994) 
 
Pentane:methylchloride 
(90:10, v/v) (7 ml) 
Saturated sodium 
carbonate (0.5 ml) 
 Acetonitrile (150µl) 
Park et al.  (1991) Hexane : isoamylalcohol 
( 98 :2, v/v) (5 ml) 
 
Sodium hydroxide 
 (2M, 300-500 µl ) 
Sulphuric acid (0.025 M, 
120 µl ) 
Direct injection 
Hariharan et al. 
(1989) 
 
Pentane : isopropanol 
(95:5, v/v) (6 ml) 
Sodium hydroxide 
 (14.8 mol/l, 5 drop) 
Perchloric acid (100 
mM, 2ml) 
Mobile phase 
(100µ) 
Midha et al.  (1988) Isopropanol : n pentane 
( 5 :95, v/v) (10 ml) 
 
Saturated sodium 
carbonate (0.5ml) 
Hydrochloric acid (0.1 
N, 1ml) 
Acetonitrile 
(40µ) 
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Table 1.2 continued 
References  Extraction solvent Basifying agent Back extraction solvent Reconstitute solvent 
 
Miller & Devane. 
(1986) 
Hexane : isoamylalcohol 
(98 :2, v/v) (6 ml) 
 
Sodium hydroxide 
 (5 M, 100 µl ) 
Hydrochloric acid (0.1 
M, 100µl) 
Direct inject 
McBurney & George. 
(1984) 
Heptane : isoamylalcohol 
(98.5 :1.5, v/v) 
 
Sodium hydroxide 
 (2 M, 1 ml) 
Sulphuric acid (0.005 M, 
2ml) 
Methanol  
Dhar & Kutt. (1984) Heptane : isoamylalcohol 
(15% in 1L) (5 ml) 
 
Sodium hydroxide 
 (1 mol/l, 0.5 ml) 
Sulphuric acid (5 mM, 
0.6ml) 
Direct injection 
Jatlow et al.  (1983) Hexane : isoamylalcohol 
( 98 :2, v/v) (10 ml) 
 
Sodium hydroxide 
 (2 M, 0.2 ml) 
Hydrochloric acid (0.1 
M, 150µl) 
Direct injection 
Miyazaki & Arita. 
(1981) 
 
Diethylether (4 ml) Sodium hydroxide 
 (1 N, 1 ml) 
Hydrochloric acid (0.1 
N, 3.5ml) 
Direct injection 
Bianchetti & Morselli. 
(1978) 
Diethyleter (5 ml) Sodium hydroxide 
 (2 N, 200 µl ) 
Hydrochloric acid (0.2 
N, 2.5ml) 
 
Hempenius et al. 
(1999) 
 
Solid phase extraction 
Hoffman & Edkinds. 
(1994) 
 
Solid phase extraction 
Cahard et al.  (1990) Solid phase extraction 
 
Abbreviation: 
ml= mililiter;  µl=microliter; M=molarity; N=normality; l=liter; mol/l=mol per liter; v/v=volume by volume; mM=milimolar 
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1.3.3  PHARMACOKINETICS OF HP AND RH 
Numerous articles related to the absorption, distribution, metabolism 
and excretion of HP in animal (Braun et al., 1967; Soujin et al., 1967) and human 
(Cressman et al., 1974) have been reported. In most of these studies, pharmacokinetic 
characteristics of HP are usually reported after a single oral and intramuscular (IM) 
(Cressman et al., 1974) or intravenous (IV) administration in healthy volunteers (Holley 
et al., 1983; Chakraborty et al., 1989) and in schizophrenic patients (Cheng et al., 
1987). A summary of the HP and RH pharmacokinetic parameters in animal and 
human are shown in Table 1.3.  
 
  HP is a lipophillic compound and therefore is rapidly absorbed from the 
gastrointestinal tract following oral administration, and undergoes a first pass 
metabolism in the liver. Due to the first-pass metabolism in the liver, plasma levels of 
HP occurs within 2 to 6 h after oral dosing (Kunka & Perel, 1989) and about 20 min 
after IM administration (Cressman et al., 1974) and the systemic bioavailability is 
approximately 75% (Adam & Fernandez 1987; Javaid, 1994). Oral bioavailability is 
about 65% after first pass metabolism (Holley et al., 1983).  
 
HP is bound to plasma protein and the free fraction in serum is reported 
to be about 8 %( Forsman & Ohman, 1977a). It is widely distributed in the body and 
crosses the blood brain barrier and is also distributed in breast milk.  
 
Pharmacokinetic studies of RH in normal volunteers (Chakraborthy et 
al., 1989; Midha et al., 1989) and schizophrenic patients (Chang et al., 1989a) have 
been reported. In a study by Chang et al (1989a), a single 10 mg dose of reduced 
haloperidol was given orally to seven male schizophrenic patients (age 43.4± 8.6 
years; weight 54.6 ± 9.0 kg). The pharmacokinetic parameter of RH is shown in Table 
1.3.
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Table 1.3  Summary of pharmacokinetic for HP and RH 
Model Route  No Dose 
(mg) 
t1/2  (h) Vd (l/kg) CL (l/h) 
 
AUC (ng.h/ml) References 
Haloperidol 
Cheng et al. 
(1987) 
 
Human 
(67 ± 16kg)  
Intravenous 
Oral  
6 
8 
1.5 - 5.0 
2.0 - 5.0 
18.8 ± 4.7 
18.1 ± 4.5 
9.5 ± 1.9 
 
33 ± 7.8 NR 
Holley et al. 
(1983) 
 
Human 
(70.9 ± 
7.0kg) 
Intravenous 
Oral 
6 
8 
0.125 
0.503 
26.2 ± 8.0 
14.5 ± 3.2 
21.7 ± 6.9 
 
49.2 ± 12 NR 
Magliozzi & 
Hollister. 
(1985) 
 
Human Intravenous 
Oral 
6 
6 
0.125 
0.500 
15.1 ± 2.5 
17.5 ± 8.7 
NR NR NR 
Forsman et al. 
(1974) 
Human  Intravenous  3 5 12.6 27 NR NR 
Cheng & Paalzow. 
(1992) 
Rats 
(190 - 250g) 
Intravenous 6 - 8 0.5 
1.0 
2.5 
1.53 
1.54 
1.54 
 
4.3 
5.6 
6.5 
86.2
a
 
82.3
a
 
80.7
a
 
5724.5 ± 4.6 
11874.2 ± 3.0 
32110.4 ± 2.9 
Wurzburger et al. 
(1981) 
Rats 
(300 - 350g) 
Intravenous  0.25 
0.5 
1.0 
2.69 
2.60 
2.50 
3.33 
4.60 
4.50 
53.2
b
 
46.7
b
 
42.2
b
 
80.1 
174 
378 
 Reduced haloperidol 
Chang et al. 
(1989a) 
Human  
(54.6  ± 9.0 
kg) 
Oral  7 10 67.0 ± 51.3 46.0 ± 20.2 0.60  ±0.30
c
 448.5 ± 336.0
d
 
Note: 
a = Clearance reported at unit ml min-1 kg-1 ; b = Clearance reported at unit ml/min 
c = Clearance reported at unit l/h/kg and d = AUC reported at unit µg.l/h 
Abbreviations:  
t1/2 = elimination half-life; Vd=apparent volume of distribution; CL=clearance; NR=not reported 
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Table 1.4 Concentration of HP and RH in rat tissues after a single intraperitoneally injection of HP or RH ( 1mg/kg body weight) ( Korpi & 
Wyatt, 1984). 
Tissue/time after injection  HP treatment   ______  RH treatment   ____________ 
     HP   RH    HP   RH 
________________________________________________________________________________________________________________ 
 
Plasma 
  10 min    0.2 ± 0.1  n.d.    0.0 ± 0.0  0.1 ± 0.1 
  30 min    0.1 ± 0.0  n.d.    0.0 ± 0.0  0.1 ± 0.0 
120 min    0.1 ± 0.0  n.d.    0.0 ± 0.0  0.0 ± 0.0 
 
Liver 
  10 min    24.0 ± 7.8  0.4 ± 0.2   6.8 ± 0.5  1.8 ± 0.1 
  30 min     6.2  ± 0.2  0.1 ± 0.0   3.1 ± 0.1  0.8 ± 0.1 
120 min      2.9  ± 0.2  0.0 ± 0.0   2.1 ± 0.1  0.3 ± 0.0 
 
Corpus striatum 
 10 min    3.4 ± 1.3  n.d.    0.2 ± 0.0  1.6 ± 1.3 
 30 min    3.2 ± 0.5  n.d.    0.5 ± 0.1  2.3 ± 0.9 
120  min    1.2 ± 0.2  n.d.    0.6 ± 0.1  0.6 ± 0.2 
 
Drug concentrations are given as mean  ±  S.E.M. (n=4) in µmol/l for plasma and in  µmol/kg wet weight for liver and corpus striatum. 
n.d.= not detected.   
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Table 1.5 Concentration of HP and RH in striatum and plasma after repeated IP injections of HP(Chang et al., 1988). 
Dose  Drug concentration_____________________________________________________________________________________ 
(mg/kg) Striatum (ng/g) _________________________  Plasma (ng/ml)___________________________________ 
  HP    RH     HP    RH 
 
0.1  138 ± 5     168 ± 10      1.8 ± 0.2       5.0 ± 0.4 
0.5  220 ± 11     433 ± 16      4.4 ± 0.4     28.8 ± 2.0 
2  436 ± 17   2158 ± 155    11.1 ± 0.6   149.6 ± 6.0 
 
All values are mean ± S.E.M. of six to eight animals 
 
 
Table 1.6  Pharmacokinetic parameters after administration of HP and RH. 
References  Subject  No Drug   Dose   pharmacokinetic parameters_________________________ 
           AUC (ng.h/ml)  CL (l/kg)  t1/2 (h)  
 
Chakraborty   Healthy volunteers 15 HP  (given HP 5 mg) 70.7 ± 33.4  NR      53.9 ± 24.5 
et al., 1989  77.6 ± 10kg   RH  (given HP 5 mg) 62.0 ± 103.1  NR      69.2 ± 23.9 
       HP  (given RH 5 mg) a   NR      a 
       RH  (given RH 5 mg) 54.5 ± 20.9  NR      73.2 ± 29.4 
 
 
Jann et al.,  Schizophrenic  6 HP  (given HP 10 mg) 200.5 ± 99.2b     1.1 ± 0.3c     21.5 ± 9.1 
1990   43 - 66 kg   RH  (given HP 10 mg)   85.0 ± 72.2b      6.2 ± 8.8c     34.0 ± 22.5 
       HP  (given RH 10 mg)   48.2 ± 66.4b  11.5 ± 10.9c     36.7 ± 48.0 
       RH  (given RH 10 mg) 432.5 ± 336.3b    0.7 ± 0.6c              71.9 ± 61.2 
Note: 
a= could not be calculated in 14 out of 15 volunteers because HP not determined given RH dose. b= AUC reported at unit  mcg.h/l.  
CL = Clearance reported as unit l/h/kg. 
Abbreviation : AUC = Area under the curve; HP = Haloperidol; RH = Reduced haloperidol; kg=kilogram; mg=miligram. 
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The liver is the major site of HP metabolism (Korpi et al., 1985). The 
metabolism of the HP in humans involves the initial cleavage of the molecule at the C-
N bond of the central chain to form an inactive piperidine and 4-fluorobenzoylpropionic 
acid metabolites (Forsman et al., 1977) (Figure 1.3) and the formation of a conjugate 
with glucuronic acid at the hydroxy group (Oida et al., 1989). HP is also metabolised 
through reduction at the benzylic ketone group to form an alcohol metabolite, known as 
reduced haloperidol (RH) (Forsman & Larsson, 1978).  
  
HP is excreted slowly in the urine and faeces. About 30% of a given 
dose is excreted in urine and about 20% of a given dose in faeces via biliary 
elimination (Beresford & Ward, 1987). Only 1% of a given dose is excreted as 
unchanged drug in the urine (Forsman et al., 1977). There is also evidence of 
enterohepatic recycling (Chakraborty et al., 1989). 
 
The interconversion between HP and RH are species specific. RH is 
oxidised back to HP in rats (Table 1.4) (Korpi & Wyatt 1984; Korpi et al., 1985a), while 
in guinea pigs reversible metabolism of HP and RH (reduction and oxidation of both 
compounds) were found (Table 1.5) (Korpi et al., 1985, 1985a; Chang et al., 1988, 
1991). The presence of RH in the plasma patients treated with HP was first reported by 
Forsman & Larsson (1978). However, the back conversion from RH to HP in human 
was not elucidated until 1987. Back conversion of HP to RH in humans was detected in 
plasma from healthy volunteer subjects.  Healthy volunteer subjects were 
administration of a single oral 5 mg dose of RH (Midha et al., 1987). Two years later, 
these authors reported the interconversion between HP and RH in 14 of 15 normal 
volunteers who received a single 5 mg dose of HP and RH separately  (Chakraborty et 
al., 1989; Midha et al., 1989). Further, Chang et al. (1989a) also reported the reversible 
metabolism of HP and RH in schizophrenic patients (Table 1.6). The enzyme 
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responsible to produce RH from HP is characteristic of a ketone reductase that is 
present in human and guinea pig hepatic cytosol (Inaba & Kovac, 1989). The reductase 
activity was dependent on nicotinamide-adenine-dinucleotide-phosphate as a cofactor 
for both humans and guinea pigs.  
 
Several metabolic pathways involved in the metabolism of HP and RH 
are mediated by cytochrome P450 isoenzymes (CYP) (Usuki et al., 1998). CYP3A4 
plays an important role and is responsible for the N-dealkylation of HP and RH (Pan et 
al., 1997; Pan et al., 1998a; Fang et al., 1997), the back oxidation of HP to RH (Pan et 
al., 1998a, Kudo & Odomi, 1998; Avent & Gillam, 1998; Fang et al., 1997) and the 
formation of pyridinum metabolite (Avent & Gillam, 1998; Fang et al., 1997; Eyles et al., 
1996). There are however, in the literature, several suggestions based on in vivo and in 
vitro studies, that CYP2D6 (Inaba et al., 1985; Tyndale et al., 1991) could also be 
involved, but the metabolic pathways are not known.  
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Figure 1.3 Metabolism of HP (Forsman et al., 1977). 
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1.3.4  DRUG INTERACTIONS 
A drug interaction usually refers to the modifications of the expected 
drug response due to exposure of the patients to other foods or drugs administered 
concomitantly. Drug interaction may include drug-drug interaction or drug-food 
interaction (Shargel & Yu, 1999). Food-drug interactions can produce negative effects 
in the safety and efficacy of drug therapy and in the nutritional status of the patients 
(Miguel et al., 2005). Many nutrients substantially interfere with the absorption or 
metabolism of drugs in the body (Anderson, 1998; Kirk, 1995). For examples, grapes 
fruit juice increase the plasma level of many drugs such as lovastatin and simvastatin 
due to naringin that inhibit their metabolism (Kantola et al., 1998). Fluoroquinolones 
binds with iron or calcium enriched foods and antacids if administered simultaneously. 
The resulting compounds excreted with little or no systemic absorption. Significant 
interaction of P-glycoproteins with cyclosporine and reduce the absorption of 
levofloxacin has been reported (Wallace et al., 2003).  
 
Many drug-drug interactions are metabolism based and related to 
cytochrome P450 (CYP) enzymes. The CYP enzyme system is a very large group of 
enzymes encoded by the P450 superfamily. CYPs are membrane bound proteins with 
an approximate molecular weight of 50 kD and contain a heme moiety (Gunaratna, 
2000). Because of the diversity of the cytochrome family a nomenclature system based 
on sequence identity is developed. This nomenclature is comprised of family and sub-
family systems. Family includes CYPs and is designated by a number after CYP. Sub-
family is the CYPs within the family and is designated by a letter following the number. 
For example, CYP2D6 is a cytochrome P450 enzyme. It belongs to family 2 and sub-
family D. The last number 6 refers to the sequence of discovery. There are about 30 
human cytochrome P450 enzymes. Only 6 of them such as CYP1A2, CYP2C9, 
CYP2C19, CYP2D6, CYP2E1 and CYP3A4 are mainly involved in drug metabolism. 
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Among these CYP3A4 is the most abundant and most clinically important isoenzymes 
in humans (Gunaratna, 2000).  
 
The enzymes involved in the metabolism of drug are altered by food and 
the co-administered drug. Enzyme induction is a drug or chemical-stimulated increase 
in enzyme activity usually due to an increase in the amount of enzyme present. 
Enzyme inhibition is substrate competition or due to direct inhibition of the drug 
metabolising enzymes, mainly CYP enzymes (Shargel & Yu, 1999). The CYP enzyme 
is important to the pharmacokinetics of psychotropic drugs. The result of inhibition is a 
higher plasma level of drug that can cause adverse effect. The result of induction is a 
lower plasma level of drug that can affect the therapeutic efficacy (Sharif, 2003). 
 
 Concomitantly administered drugs may affect the pharmacokinetics of 
HP by influencing its metabolic clearance and its ability to bind to plasma proteins, and 
by causing alterations in hepatic blood flow. HP appears to be a moderately extracted 
drug. On a theoretical basis, alterations in protein binding of drugs with a low extraction 
ratio would have no influence on the pharmacokinetics of unbound drug at steady state. 
On the other hand, alterations of plasma protein binding of high extraction drugs would 
be predicted to cause a change in the clearance of unbound drug (Wilkinson & Shand, 
1975; Nies et al., 1976; Blaschke, 1977).  
 
Table 1.7 shows pharmacokinetic interactions between HP and other 
drugs. Anticonvulsant drugs such as carbamazepine, phenytoin and phenobarbitone 
are classified as enzyme inducers. Clinically significant decrease in plasma 
concentration of HP was reported when coadministered with carbamazepine (Jann et 
al., 1985; Kidron, et al., 1985; Arana et al., 1986). Another similar study showed 
decreased plasma concentration of HP when co-administered with phenytoin and 
phenobarbitat (Linnoila et al., 1980). There have been several reports on 
